NasdaqGS:GOSSBiotechs
Barclays Upgrade and 81% Institutional Ownership Could Be A Game Changer For Gossamer Bio (GOSS)
Earlier this week, Barclays upgraded Gossamer Bio to a “Strong Buy” rating, as institutional ownership climbed above 81% and attention centered on its lead investigational drug seralutinib for pulmonary arterial hypertension and related conditions.
This combination of a stronger Wall Street stance and concentrated institutional exposure highlights how closely investors are watching seralutinib’s clinical and commercial potential.
Against this backdrop, we’ll explore how Barclays’ upgrade and...